Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment

被引:139
作者
Gallagher, RM
Kunkel, R
机构
[1] Univ Med & Dent New Jersey, Sch Osteopath Med, Stratford, NJ 08084 USA
[2] Cleveland Clin, Dept Neurol, Cleveland, OH 44106 USA
来源
HEADACHE | 2003年 / 43卷 / 01期
关键词
migraine; adverse effects; self-management; almotriptan;
D O I
10.1046/j.1526-4610.2003.03006.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives.-To determine the level of concern among migraineurs about migraine prescription medication tolerability and adverse effects and the impact of these concerns on their self-management of migraine. Methods.-Self-completion questionnaires were mailed from the National Family Opinion household panel to a prequalified sample of 4000 adults (aged 18 years or older) who reported severe headache and migraine. Those who met the International Headache Society symptom criteria for migraine and reported use of prescription medication to treat their migraines were included in the descriptive analysis. Results.-A total of 2444 (61%) sufferers of severe headache/migraine returned a completed survey, and 56% of these (n=1160) met the target criteria for the study. Of those meeting the criteria, pain relief and speed of onset were important product attributes for 75% to 77% of sufferers, and the absence of adverse effects was important to over 40%. Two-thirds of sufferers specifically had delayed or avoided taking a current prescription medication because of concerns about adverse effects. These concerns led to a delay in taking medication in 37% of treated migraine episodes and to medication avoidance in 44% of untreated attacks during the previous 6 months, resulting in more intensive and longer duration of pain, the need to rest and cancel social activities, and suboptimal performance. Almost 8 of 10 (79%) sufferers showed an interest in trying a novel product with similar efficacy but fewer adverse effects than other prescription migraine medications. Conclusions.-Adverse effects are an important factor in migraine management, and concern about adverse effects significantly affected patient compliance.
引用
收藏
页码:36 / 43
页数:8
相关论文
共 17 条
[1]   Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan [J].
Colman, SS ;
Brod, MI ;
Krishnamurthy, A ;
Rowland, CR ;
Jirgens, KJ ;
Gomez-Mancilla, B .
CLINICAL THERAPEUTICS, 2001, 23 (01) :127-145
[2]   CLINICAL-EXPERIENCES FROM SWEDEN ON THE USE OF SUBCUTANEOUSLY ADMINISTERED SUMATRIPTAN IN MIGRAINE AND CLUSTER HEADACHE [J].
DAHLOF, C ;
EKBOM, K ;
PERSSON, L .
ARCHIVES OF NEUROLOGY, 1994, 51 (12) :1256-1261
[3]   How to assess patient preference of migraine treatments [J].
Dahlöf, C .
CEPHALALGIA, 1999, 19 :2-6
[4]   Determinants of patient satisfaction with migraine therapy [J].
Davies, GM ;
Santanello, N ;
Lipton, R .
CEPHALALGIA, 2000, 20 (06) :554-560
[5]   IMPACT OF MIGRAINE AND TENSION-TYPE HEADACHE ON LIFE-STYLE, CONSULTING BEHAVIOR, AND MEDICATION USE - A CANADIAN POPULATION SURVEY [J].
EDMEADS, J ;
FINDLAY, H ;
TUGWELL, P ;
PRYSEPHILLIPS, W ;
NELSON, RF ;
MURRAY, TJ .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1993, 20 (02) :131-137
[6]  
Gawel MJ, 2001, CAN J NEUROL SCI, V28, P30
[7]  
HAMELSKY SW, 2001, CEPHALALGIA, V21, P336
[8]   What do patients with migraine want from acute migraine treatment? [J].
Lipton, RB ;
Hamelsky, SW ;
Dayno, JM .
HEADACHE, 2002, 42 :S3-S9
[9]   Prevalence and burden of migraine in the United States: Data from the American Migraine Study II [J].
Lipton, RB ;
Stewart, WF ;
Diamond, S ;
Diamond, ML ;
Reed, M .
HEADACHE, 2001, 41 (07) :646-657
[10]   Pharmacologic profile and clinical efficacy of rizatriptan [J].
Lipton, RB .
HEADACHE, 1999, 39 :S9-S15